The menopause health gap is a pressing issue that affects millions of women worldwide, yet it remains largely hidden from public discourse. More than half of women experience vaginal dryness during or after menopause, and shockingly, only a small percentage ever discuss it with their doctor. This silence perpetuates an injustice and presents an opportunity for innovation in women's health.
As an entrepreneur, I've always been drawn to solving problems that matter. When I delved into women's health, I noticed a stark disparity in innovation. While there's been significant focus on fertility and pregnancy, perimenopause and its symptoms, such as vaginal dryness, have been largely overlooked. This is particularly concerning given that millennials, a generation known for challenging norms and demanding better, are now entering this stage of life.
Recognizing this gap, I co-founded Biolae with Maryalice Rosa, sharing her passion for women's health. Our mission is to address the lack of clinically validated, non-hormonal solutions for perimenopause. In conversations with healthcare professionals, it became clear that the science behind many available products was lacking. Therefore, we made clinical validity our top priority.
At Biolae, we set a new standard for evidence-based products. Our ingredients are backed by gold-standard clinical trials, dosed at therapeutic levels, and every batch is independently tested for purity and potency. We established a Scientific Advisory Board to ensure these standards are met.
One of our key insights is that women don't just connect with products; they connect with brands that understand them. In the healthcare industry, there's often a trade-off between efficacy and other important factors like design, experience, and community. I wanted to challenge this notion and prove that these aspects can coexist with efficacy.
Our upcoming launch of Australia's first TGA-listed hyaluronic acid pessary is a testament to our commitment. This product, developed over three years, represents a significant milestone in our journey. Launching a first-to-market medical device in a personal category comes with immense responsibility, and I approach it with the utmost care.
Vaginal dryness is often associated with menopause, but it's a symptom that affects women in various stages of life. It can occur postpartum, during stressful periods, or as a side effect of certain medications. By separating vaginal dryness from the menopause umbrella, we aim to educate women and bring this often-taboo topic into the open.
While menopause conversations have become more acceptable, vaginal dryness remains a silent issue. This gap between prevalence and discussion is where we believe the real impact lies. Our goal is to change this dynamic and empower women to take charge of their health.
Launching in underserved spaces is exhilarating. As a startup, we're pioneering a new path by introducing a first-to-market medical device in consumer health, addressing an overlooked symptom. This approach is both challenging and rewarding, and it's what drives me.
Our marketing strategy, Not-So-Dry July, is designed to educate women about vaginal dryness while making the conversation less intimidating. Humor, when used thoughtfully, can effectively break down stigma and encourage open dialogue. Balancing this delicate approach is crucial to our success.
Looking ahead, our next big step is entering the pharmacy market. Historically, the menopause section has been relegated to the bottom shelf, symbolizing its undervalued status. Our goal is to reshape how retailers perceive menopause and the role these products play in women's lives.
In the past three years, we've encountered setbacks, pivots, and moments of uncertainty, typical challenges for any startup. Yet, I feel we're just at the beginning, and that's an exciting prospect. Women's health is gaining the attention it deserves, but there are still numerous unmet needs waiting to be addressed, and that's what truly drives my passion.
